Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
First Claim
Patent Images
1. A compound having Formula II:
- (SEQ ID NO;
13488)5′
-usascs asau ucU GAu Gag gcg aaa gcc Gaa Aag aca aB-3′
wherein each a is 2′
-O-methyl adenosine nucleotide, each g is a 2′
-O-methyl guanosine nucleotide, each c is a 2′
-O-methyl cytidine nucleotide, each u is a 2′
-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2′
-deoxy-2′
-C-allyl uridine, and B is an inverted deoxyabasic moiety.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.
49 Citations
20 Claims
-
1. A compound having Formula II:
- (SEQ ID NO;
13488)5′
-usascs asau ucU GAu Gag gcg aaa gcc Gaa Aag aca aB-3′
wherein each a is 2′
-O-methyl adenosine nucleotide, each g is a 2′
-O-methyl guanosine nucleotide, each c is a 2′
-O-methyl cytidine nucleotide, each u is a 2′
-O-methyl uridine nucleotide, each A is adenosine, each G is guanosine, each s individually represents a phosphorothioate internucleotide linkage, U is 2′
-deoxy-2′
-C-allyl uridine, and B is an inverted deoxyabasic moiety. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- (SEQ ID NO;
Specification